Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 3, 2009, Pages 438-444

  Wakabayashi, H ^a   Griffiths, A E ^a   Fay, Philip J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Factor VIII; Factor Xa; Guanidinium; Protein stability; Thrombin generation

Indexed keywords

ASPARTIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; GLUTAMIC ACID; GUANIDINE; MUTANT PROTEIN; PROTEIN SUBUNIT; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN;

ARTICLE; DISSOCIATION; GENETIC VARIABILITY; HUMAN; HYDROPHOBICITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; TEMPERATURE SENSITIVITY; THERMOSTABILITY;

AMINO ACID SUBSTITUTION; AMINO ACIDS, ACIDIC; FACTOR VIII; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN SUBUNITS; STATIC ELECTRICITY; THROMBIN;

EID: 59849090731     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03256.x     Document Type: Article

References (26)

1. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
2. Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys 1988; 262: 525-31.
3. Wakabayashi H, Koszelak ME, Mastri M, Fay PJ. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry 2001; 40: 10293-300.
4. 2+ binding site required for cofactor activity. J Biol Chem 2004; 279: 12677-84.
5. Shen BW, Spiegel PC, Chang CH, Huh JW, Lee JS, Kim J, Kim YH, Stoddard BL. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-7.
6. Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: Implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
7. 2+. Biochim Biophys Acta 2006; 1764: 1094-101.
8. Ansong C, Fay PJ. Factor VIII A3 domain residues 1954-1961 represent an a1 domain-interactive site. Biochemistry 2005; 44: 8850-7.
9. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-62.
10. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-92.
11. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-6.
12. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271: 6027-32.
13. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: Evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-83.
14. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-91.
15. Hakeos WH, Miao H, Sirachainan N, Kemball-Cook G, Saenko EL, Kaufman RJ, Pipe SW. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002; 88: 781-7.
16. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-8.
17. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-6.
18. Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem 2008; 283: 11645-51.
19. Wakabayashi H, Varfaj F, Deangelis J, Fay PJ. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood 2008; 112: 2761-9.
20. Sammond DW, Eletr ZM, Purbeck C, Kimple RJ, Siderovski DP, Kuhlman B. Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. J Mol Biol 2007; 371: 1392-404.
21. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-40.
22. Doering C, Parker ET, Healey JF, Craddock HN, Barrow RT, Lollar P. Expression and characterization of recombinant murine factor VIII. Thromb Haemost 2002; 88: 450-8.
23. Wakabayashi H, Su YC, Ahmad SS, Walsh PN, Fay PJ. A Glu113Ala mutation within a factor VIII Ca(2+)-binding site enhances cofactor interactions in factor Xase. Biochemistry 2005; 44: 10298-304.
24. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
25. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
26. Radtke KP, Griffin JH, Riceberg J, Gale AJ. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. J Thromb Haemost 2007; 5: 102-8.